Polar Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Polar Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$10.8M	Sell	260,703 -734,911	-74%	-$31.7M	0.08%	176
2020 Q2	$48.3M	Sell	995,614 -278,752	-22%	-$13.4M	0.42%	76
2020 Q1	$53.8M	Buy	1,274,366 +499,988	+65%	+$20.6M	0.58%	50
2019 Q4	$33.1M	Buy	+774,378	New	+$33.7M	0.29%	117
2018 Q1	–	Sell	-50,000	Closed	-$1.51M	–	256
2017 Q4	$1.51M	Sell	50,000 -25,000	-33%	-$799K	0.02%	238
2017 Q3	$2.83M	Sell	75,000 -100,000	-57%	-$3.25M	0.03%	218
2017 Q2	$4.88M	Hold	175,000	–	–	0.07%	191
2017 Q1	$6.02M	Buy	175,000 +155,000	+775%	+$5.47M	0.09%	172
2016 Q4	$577K	Buy	20,000 +8,750	+78%	+$231K	0.01%	251
2016 Q3	$358K	Sell	11,250 -19,143	-63%	-$649K	0.01%	250
2016 Q2	$987K	Buy	+30,393	New	+$1.02M	0.02%	244
2016 Q1	–	Sell	-14,595	Closed	-$520K	–	262
2015 Q4	$520K	Sell	14,595 -6,738	-32%	-$237K	0.01%	249
2015 Q3	$705K	Sell	21,333 -9,142	-30%	-$380K	0.01%	250
2015 Q2	$1.28M	Buy	30,475 +4,577	+18%	+$177K	0.02%	244
2015 Q1	$844K	Buy	25,898 +2,356	+10%	+$81K	0.02%	253
2014 Q4	$747K	Buy	23,542 +14,933	+173%	+$423K	0.01%	244
2014 Q3	$213K	Buy	+8,609	New	+$201K	﹤0.01%	266

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Polar Capital's ACAD Position: Q3 2020 in Review

Polar Capital reduced its Acadia Pharmaceuticals (ACAD) stake by 74% in Q3 2020, selling an estimated $31.7M and leaving 260,703 shares worth $10.8M. The position accounts for 0.08% of the portfolio, ranked #176.

Polar Capital first reported a position in ACAD in Q3 2014 and has held it in 17 quarters since. The position peaked at $53.8M in Q1 2020. 266 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

Polar Capital held 260,703 shares of Acadia Pharmaceuticals worth $10.8M as of Q3 2020.
Polar Capital sold 734,911 Acadia Pharmaceuticals shares in Q3 2020, an estimated $31.7M.
Acadia Pharmaceuticals made up 0.08% of Polar Capital's portfolio in Q3 2020, its #176 holding.
Polar Capital first reported a position in Acadia Pharmaceuticals in Q3 2014 and has held it in 17 quarters since.
Polar Capital's Acadia Pharmaceuticals position peaked at $53.8M in Q1 2020.
266 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.